Moderna Partners with Takeda & the Government of Japan to Supply Additional 50 Million Doses of Moderna’s COVID-19 Vaccine ...
July 20 2021 - 6:42AM
Business Wire
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering
messenger RNA (mRNA) therapeutics and vaccines, today announced
that the Ministry of Health, Labour and Welfare of Japan (MHLW) and
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE: TAK) have
agreed to purchase and distribute an additional 50 million doses of
Moderna’s COVID-19 vaccine and its updated variant booster vaccine
candidate, if authorized, to begin delivery in 2022.
This new supply agreement is in addition to the prior agreement
for 50 million doses in 2021 resulting in a total of 100 million
doses for Japan. Moderna is responsible for the manufacture and
supply of Moderna’s vaccine candidate, and Takeda, with the support
of the MHLW and Moderna, is responsible for all import, local
regulatory, development and distribution activities in Japan for
these additional 50 million doses beginning in 2022.
“We thank the MHLW and Takeda for their support and for
partnering with us to bring our mRNA COVID-19 vaccine to Japan,”
said Stéphane Bancel, Moderna’s Chief Executive Officer. “We remain
committed to making our vaccine available around the world as we
seek to address the pandemic.”
About Moderna
In 10 years since its inception, Moderna has transformed from a
science research-stage company advancing programs in the field of
messenger RNA (mRNA), to an enterprise with a diverse clinical
portfolio of vaccines and therapeutics across six modalities, a
broad intellectual property portfolio in areas including mRNA and
lipid nanoparticle formulation, and an integrated manufacturing
plant that allows for both clinical and commercial production at
scale and at unprecedented speed. Moderna maintains alliances with
a broad range of domestic and overseas government and commercial
collaborators, which has allowed for the pursuit of both
groundbreaking science and rapid scaling of manufacturing. Most
recently, Moderna’s capabilities have come together to allow the
authorized use of one of the earliest and most-effective vaccines
against the COVID-19 pandemic.
Moderna’s mRNA platform builds on continuous advances in basic
and applied mRNA science, delivery technology and manufacturing,
and has allowed the development of therapeutics and vaccines for
infectious diseases, immuno-oncology, rare diseases, cardiovascular
diseases and auto-immune diseases. Today, 24 development programs
are underway across these therapeutic areas, with 15 programs
having entered the clinic. Moderna has been named a top
biopharmaceutical employer by Science for the past six years. To
learn more, visit www.modernatx.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including regarding: the Company’s development of
a vaccine to protect against the SARS-CoV-2 virus (mRNA-1273, also
referred to as the Moderna COVID-19 Vaccine), as well as booster
vaccine candidates; the Company’s agreement to supply the vaccine
to the government of Japan; the arrangements between the Company,
Takeda and Japanese regulatory authorities for the importation of
the vaccine; and the anticipated number of doses and timing for
delivery of vaccine supply. The forward-looking statements in this
press release are neither promises nor guarantees, and you should
not place undue reliance on these forward-looking statements
because they involve known and unknown risks, uncertainties, and
other factors, many of which are beyond Moderna’s control and which
could cause actual results to differ materially from those
expressed or implied by these forward-looking statements. These
risks, uncertainties, and other factors include those other risks
and uncertainties described under the heading “Risk Factors” in
Moderna’s most recent Annual Report on Form 10-K filed with the
U.S. Securities and Exchange Commission (SEC) and in subsequent
filings made by Moderna with the SEC, which are available on the
SEC’s website at www.sec.gov. Except as required by law, Moderna
disclaims any intention or responsibility for updating or revising
any forward-looking statements contained in this press release in
the event of new information, future developments or otherwise.
These forward-looking statements are based on Moderna’s current
expectations and speak only as of the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210720005641/en/
Moderna
Media: Colleen Hussey Director, Corporate Communications
617-335-1374 Colleen.Hussey@modernatx.com
Investors: Lavina Talukdar Senior Vice President &
Head of Investor Relations 617-209-5834
Lavina.Talukdar@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Sep 2023 to Sep 2024